207 related articles for article (PubMed ID: 34417224)
1. PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by
Li J; Hlavka-Zhang J; Shrimp JH; Piper C; Dupéré-Richér D; Roth JS; Jing D; Casellas Román HL; Troche C; Swaroop A; Kulis M; Oyer JA; Will CM; Shen M; Riva A; Bennett RL; Ferrando AA; Hall MD; Lock RB; Licht JD
Cancer Discov; 2022 Jan; 12(1):186-203. PubMed ID: 34417224
[TBL] [Abstract][Full Text] [Related]
2. The NSD2 p.E1099K Mutation Is Enriched at Relapse and Confers Drug Resistance in a Cell Context-Dependent Manner in Pediatric Acute Lymphoblastic Leukemia.
Pierro J; Saliba J; Narang S; Sethia G; Saint Fleur-Lominy S; Chowdhury A; Qualls A; Fay H; Kilberg HL; Moriyama T; Fuller TJ; Teachey DT; Schmiegelow K; Yang JJ; Loh ML; Brown PA; Zhang J; Ma X; Tsirigos A; Evensen NA; Carroll WL
Mol Cancer Res; 2020 Aug; 18(8):1153-1165. PubMed ID: 32332049
[TBL] [Abstract][Full Text] [Related]
3. Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia.
Jaffe JD; Wang Y; Chan HM; Zhang J; Huether R; Kryukov GV; Bhang HE; Taylor JE; Hu M; Englund NP; Yan F; Wang Z; Robert McDonald E; Wei L; Ma J; Easton J; Yu Z; deBeaumount R; Gibaja V; Venkatesan K; Schlegel R; Sellers WR; Keen N; Liu J; Caponigro G; Barretina J; Cooke VG; Mullighan C; Carr SA; Downing JR; Garraway LA; Stegmeier F
Nat Genet; 2013 Nov; 45(11):1386-91. PubMed ID: 24076604
[TBL] [Abstract][Full Text] [Related]
4. An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia.
Swaroop A; Oyer JA; Will CM; Huang X; Yu W; Troche C; Bulic M; Durham BH; Wen QJ; Crispino JD; MacKerell AD; Bennett RL; Kelleher NL; Licht JD
Oncogene; 2019 Jan; 38(5):671-686. PubMed ID: 30171259
[TBL] [Abstract][Full Text] [Related]
5. NSD2 E1099K drives relapse in pediatric acute lymphoblastic leukemia by disrupting 3D chromatin organization.
Narang S; Evensen NA; Saliba J; Pierro J; Loh ML; Brown PA; Kolekar P; Mulder H; Shao Y; Easton J; Ma X; Tsirigos A; Carroll WL
Genome Biol; 2023 Apr; 24(1):64. PubMed ID: 37016431
[TBL] [Abstract][Full Text] [Related]
6. Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes.
Wang J; Duan Z; Nugent Z; Zou JX; Borowsky AD; Zhang Y; Tepper CG; Li JJ; Fiehn O; Xu J; Kung HJ; Murphy LC; Chen HW
Cancer Lett; 2016 Aug; 378(2):69-79. PubMed ID: 27164560
[TBL] [Abstract][Full Text] [Related]
7. BTG1 regulates glucocorticoid receptor autoinduction in acute lymphoblastic leukemia.
van Galen JC; Kuiper RP; van Emst L; Levers M; Tijchon E; Scheijen B; Waanders E; van Reijmersdal SV; Gilissen C; van Kessel AG; Hoogerbrugge PM; van Leeuwen FN
Blood; 2010 Jun; 115(23):4810-9. PubMed ID: 20354172
[TBL] [Abstract][Full Text] [Related]
8. High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2.
Coussens NP; Kales SC; Henderson MJ; Lee OW; Horiuchi KY; Wang Y; Chen Q; Kuznetsova E; Wu J; Chakka S; Cheff DM; Cheng KC; Shinn P; Brimacombe KR; Shen M; Simeonov A; Lal-Nag M; Ma H; Jadhav A; Hall MD
J Biol Chem; 2018 Aug; 293(35):13750-13765. PubMed ID: 29945974
[TBL] [Abstract][Full Text] [Related]
9. Genetic variations in the glucocorticoid receptor gene are not related to glucocorticoid resistance in childhood acute lymphoblastic leukemia.
Tissing WJ; Meijerink JP; den Boer ML; Brinkhof B; van Rossum EF; van Wering ER; Koper JW; Sonneveld P; Pieters R
Clin Cancer Res; 2005 Aug; 11(16):6050-6. PubMed ID: 16115950
[TBL] [Abstract][Full Text] [Related]
10. Defining the NSD2 interactome: PARP1 PARylation reduces NSD2 histone methyltransferase activity and impedes chromatin binding.
Huang X; LeDuc RD; Fornelli L; Schunter AJ; Bennett RL; Kelleher NL; Licht JD
J Biol Chem; 2019 Aug; 294(33):12459-12471. PubMed ID: 31248990
[TBL] [Abstract][Full Text] [Related]
11. Loss of TBL1XR1 disrupts glucocorticoid receptor recruitment to chromatin and results in glucocorticoid resistance in a B-lymphoblastic leukemia model.
Jones CL; Bhatla T; Blum R; Wang J; Paugh SW; Wen X; Bourgeois W; Bitterman DS; Raetz EA; Morrison DJ; Teachey DT; Evans WE; Garabedian MJ; Carroll WL
J Biol Chem; 2014 Jul; 289(30):20502-15. PubMed ID: 24895125
[TBL] [Abstract][Full Text] [Related]
12. Increasing G9a automethylation sensitizes B acute lymphoblastic leukemia cells to glucocorticoid-induced death.
Poulard C; Baulu E; Lee BH; Pufall MA; Stallcup MR
Cell Death Dis; 2018 Oct; 9(10):1038. PubMed ID: 30305606
[TBL] [Abstract][Full Text] [Related]
13. Glucocorticoid resistance in two key models of acute lymphoblastic leukemia occurs at the level of the glucocorticoid receptor.
Schmidt S; Irving JA; Minto L; Matheson E; Nicholson L; Ploner A; Parson W; Kofler A; Amort M; Erdel M; Hall A; Kofler R
FASEB J; 2006 Dec; 20(14):2600-2. PubMed ID: 17077285
[TBL] [Abstract][Full Text] [Related]
14. S-adenosylhomocysteine (AdoHcy)-dependent methyltransferase inhibitor DZNep overcomes breast cancer tamoxifen resistance via induction of NSD2 degradation and suppression of NSD2-driven redox homeostasis.
Wang Q; Zheng J; Zou JX; Xu J; Han F; Xiang S; Liu P; Chen HW; Wang J
Chem Biol Interact; 2020 Feb; 317():108965. PubMed ID: 32001260
[TBL] [Abstract][Full Text] [Related]
15. Receptor mutation is not a common mechanism of naturally occurring glucocorticoid resistance in leukaemia cell lines.
Beesley AH; Weller RE; Senanayake S; Welch M; Kees UR
Leuk Res; 2009 Feb; 33(2):321-5. PubMed ID: 18789525
[TBL] [Abstract][Full Text] [Related]
16. Glucocorticoid-induced glucocorticoid-receptor expression and promoter usage is not linked to glucocorticoid resistance in childhood ALL.
Tissing WJ; Meijerink JP; Brinkhof B; Broekhuis MJ; Menezes RX; den Boer ML; Pieters R
Blood; 2006 Aug; 108(3):1045-9. PubMed ID: 16574952
[TBL] [Abstract][Full Text] [Related]
17. Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma.
Liu J; Xie Y; Guo J; Li X; Wang J; Jiang H; Peng Z; Wang J; Wang S; Li Q; Ye L; Zhong Y; Zhang Q; Liu X; Lonard DM; Wang J; O'Malley BW; Liu Z
Nat Commun; 2021 Feb; 12(1):1022. PubMed ID: 33589584
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition.
Bachmann PS; Piazza RG; Janes ME; Wong NC; Davies C; Mogavero A; Bhadri VA; Szymanska B; Geninson G; Magistroni V; Cazzaniga G; Biondi A; Miranda-Saavedra D; Göttgens B; Saffery R; Craig JM; Marshall GM; Gambacorti-Passerini C; Pimanda JE; Lock RB
Blood; 2010 Oct; 116(16):3013-22. PubMed ID: 20647567
[TBL] [Abstract][Full Text] [Related]
19. Histone methyltransferase NSD2 regulates apoptosis and chemosensitivity in osteosarcoma.
He C; Liu C; Wang L; Sun Y; Jiang Y; Hao Y
Cell Death Dis; 2019 Jan; 10(2):65. PubMed ID: 30683853
[TBL] [Abstract][Full Text] [Related]
20. Opposing effects of KDM6A and JDP2 on glucocorticoid sensitivity in T-ALL.
Levinson AL; Tjoa K; Huang B; Meyer LK; Kim MO; Brady SW; Zhang J; Shannon K; Wandler AM
Blood Adv; 2023 Jul; 7(14):3479-3484. PubMed ID: 36897249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
